Vaxil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Israel’s Leading Tert...
May 05 2020 - 8:00AM
VAXIL BIO LTD. (“
Vaxil” or the
“
Company”) (TSX VENTURE: VXL), an innovative
immunotherapy biotech company specializing in cancer and infectious
diseases, is pleased to announce the signing of a collaboration
agreement between the Company and The Medical Research,
Infrastructure, and Health Services Fund of the Tel Aviv Medical
Center (the “
Tel Aviv Medical Center”) to advance
the Company’s research program to develop a potential peptide
vaccine against COVID-19.
This agreement provides Vaxil with vital access
to Tel Aviv Medical Center’s research resources including their
unique bank of biological samples and its advanced research
infrastructure. Dr. David Hagin, Director of the Allergy and
Clinical Immunology Unit, will progress our pre-clinical work and
clinical trials.
“This collaboration agreement is an central
milestone in the pre-clinical stage of our COVID-19 vaccine
candidate research, and provides a clear pathway to potential
clinical trials during 2020”, said David Goren, Vaxil’s Chairman
and Chief Executive Officer. He continued to say “the The Aviv
Medical Center is a leading hospital and is at the forefront of
fighting the COVID-19 pandemic in Israel. We look forward to
working with Dr. Hagin and their world-class medical and research
teams on this program.”
Dr. Hagin added “Use of the signal peptide
platform, which targets infected cells rather than the virus is
unique and exciting. I see great potential in this innovative
approach to develop a potential COVID-19 vaccine. We share Vaxil’s
vision of creating a vaccine quickly for the benefit of people all
over the world.”
The Company does not anticipate the need to
raise additional funds to finance this work.
The Company is not making any express or implied
claims that it has completed developing or will be successful in
developing a vaccine to treat COVID-19 (or SARS-CoV-2) at this
time.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech
company focused on its novel approach to targeting prominent cancer
markers and infectious diseases. Its lead product ImMucin™
successfully completed a Phase 1/2 clinical trial in multiple
myeloma and received orphan drug status from the FDA and EMA. The
company continues to develop ImMucintm and is also developing a
tuberculosis vaccine / treatment that has demonstrated promising
preliminary results with further preclinical evaluation underway at
a top US academic and research institution. Additional indications
and mAb candidates are under evaluation as immuno-oncology and
infectious disease treatments alone and in combination with other
treatments.
Vaxil exploits the unique properties of signal
peptide domains on crucial proteins to develop targeted therapies
against cancer targets and infectious disease pathogens. These
signal peptide domains are identified by VaxHit™, Vaxil’s
proprietary bioinformatic approach. These SPs induce a robust T-
and B-cell response across wide and varied HLA subtypes, while
acting as true, universal neoantigens. The peptide platform targets
these cells by “educating” or specifically activating the immune
system to recognize and attack the affected cells. In addition,
Vaxil’s mAb platform directly recognizes the target protein
expressed on malignant cells and recruits other elements of the
immune system to lyse those cells.
Disclaimer: The Company cautions that COVID-19
Vaccine Development is still under early stage research and
development and is not making any express or implied claims that it
has the ability to eliminate the COVID-19 virus at this time. The
TSX Venture Exchange Inc. has in no way passed upon the merits of
the Company has neither approved nor disapproved the contents of
this press release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. This news release contains
forward-looking information, which involves known and unknown
risks, uncertainties and other factors that may cause actual events
to differ materially from current expectation. Important factors -
including the availability of funds, the results of financing
efforts, the results of exploration activities -- that could cause
actual results to differ materially from the Company's expectations
are disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. This press
release does not constitute an offer to sell or a solicitation of
an offer to sell any of the securities described herein in the
United States or elsewhere. These securities have not been, and
will not be, registered in the United States Securities Act of
1933, as amended, or any state securities laws, and may not be
offered or sold in the United States or to U.S. persons unless
registered or exempt therefrom.CONTACT INFORMATIONFor further
information please visit http://vaxil-bio.com/ or
contact: David Goren, CEO -- david@vaxil-bio.com, +972 (52)
720-6000
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Apr 2023 to Apr 2024